Abimbola Farinde, PharmD, MS, FASCP, FACA




Drugs in Perspective: Dalvance

September 05, 2014

Dalvance (dalbavancin) is the first and only intravenous antibiotic was approved on May 2014 to treat ABSSSIs with a 2-dose regimen of 1,000 mg once week and later on a 500 mg that is given over a 30-minute time span

Drugs in Perspective: Tasimelteon (Hetlioz)

August 06, 2014

Hetlioz (tasimelteon) is a melatonin receptor agonist, similar to Rozerem (ramelteon) that was approved by FDA in January 2014 for the treatment of N24HSWS caused by a completely blind person’s inability to regulate their internal clock.

Drugs in Perspective: Aptiom (eslicarbazepine acetate)

July 11, 2014

Aptiom (eslicarbazepine acetate) is an oral antiepileptic tablet that was approved by FDA on November 8, 2013, as an add-on medication to treat seizure disorders that can be associated with epilepsy.

Drugs in Perspective: Zohydro ER (hydrocodone bitartrate extended release)

June 09, 2014

Pain management is gradually becoming a topic of conversation and gaining considerable attention as it relates to providing quality services for those with acute or chronic pain ailments. Pain can affect millions of Americans and it contributes significantly to national rates of morbidity, mortality, and disability.